Compugen Ltd.
A clinical-stage company developing cancer immunotherapies using an AI platform.
CGEN | TA
Overview
Corporate Details
- ISIN(s):
- IL0010852080
- LEI:
- Country:
- Israel
- Address:
- 26 Harokmim St., Bldg D, 5885849 Holon
- Website:
- https://www.cgen.com/
Description
Compugen Ltd. is a clinical-stage therapeutic discovery and development company specializing in cancer immunotherapy. A pioneer in its field, the company leverages a proprietary, broadly applicable, and predictive AI-powered computational discovery platform to identify novel drug targets. Its primary focus is on developing innovative, first-in-class therapeutics designed to modulate the tumor microenvironment and enhance anti-tumor immune responses. Compugen's mission is to advance its pipeline of drug candidates to address patient populations unresponsive to current immunotherapy treatments.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2023-12-19 15:11 |
6K-License Agreement with Gilead and entitlement to receive a milestone payment…
|
English | 36.3 KB | ||
| 2023-12-19 15:09 |
Compugen will be Eligible to Receive $10 Million Milestone Payment upon Dosing …
|
English | 107.2 KB | ||
| 2023-12-19 15:09 |
Compugen will be Eligible to Receive $10 Million Milestone Payment upon Dosing …
|
English | 36.4 KB | ||
| 2023-12-19 15:04 |
to Host Conference Call to Discuss Exclusive License Agreement with Gilead
|
English | 93.3 KB | ||
| 2023-12-19 15:04 |
to Host Conference Call to Discuss Exclusive License Agreement with Gilead
|
English | 36.3 KB | ||
| 2023-12-19 14:59 |
Gilead and Compugen Announce Exclusive License Agreement for Novel Pre-Clinical…
|
English | 145.9 KB | ||
| 2023-12-19 14:59 |
Gilead and Compugen Announce Exclusive License Agreement for Novel Pre-Clinical…
|
English | 36.3 KB | ||
| 2023-11-07 14:59 |
Compugen Reports Third Quarter 2023 Results
|
English | 89.3 KB | ||
| 2023-11-07 14:59 |
Compugen Reports Third Quarter 2023 Results
|
English | 36.4 KB | ||
| 2023-11-06 14:59 |
Compugen’s COM701 (anti-PVRIG) Mediates Anti-Tumor Activity in Patients Typical…
|
English | 77.5 KB | ||
| 2023-11-06 14:59 |
Compugen’s COM701 (anti-PVRIG) Mediates Anti-Tumor Activity in Patients Typical…
|
English | 36.4 KB | ||
| 2023-11-03 23:34 |
Compugen Announces Receipt of Nasdaq Minimum Bid Price Notification
|
English | 71.4 KB | ||
| 2023-11-03 23:34 |
Compugen Announces Receipt of Nasdaq Minimum Bid Price Notification
|
English | 36.3 KB | ||
| 2023-10-31 15:59 |
Compugen to Present New Data at SITC 2023 Suggesting Leading Edge of AntiIL18 …
|
English | 109.7 KB | ||
| 2023-10-31 15:59 |
Compugen to Present New Data at SITC 2023 Suggesting Leading Edge of AntiIL18 …
|
English | 36.3 KB |
Automate Your Workflow. Get a real-time feed of all Compugen Ltd. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Compugen Ltd.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Compugen Ltd. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
